[go: up one dir, main page]

AU1071200A - Systems for oral delivery - Google Patents

Systems for oral delivery

Info

Publication number
AU1071200A
AU1071200A AU10712/00A AU1071200A AU1071200A AU 1071200 A AU1071200 A AU 1071200A AU 10712/00 A AU10712/00 A AU 10712/00A AU 1071200 A AU1071200 A AU 1071200A AU 1071200 A AU1071200 A AU 1071200A
Authority
AU
Australia
Prior art keywords
systems
oral delivery
oral
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU10712/00A
Inventor
Gregory John Russell-Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotech Australia Pty Ltd
Original Assignee
Biotech Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotech Australia Pty Ltd filed Critical Biotech Australia Pty Ltd
Publication of AU1071200A publication Critical patent/AU1071200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • A61K38/58Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU10712/00A 1998-10-19 1999-10-18 Systems for oral delivery Abandoned AU1071200A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10482798P 1998-10-19 1998-10-19
US60104827 1998-10-19
PCT/IB1999/001872 WO2000022909A2 (en) 1998-10-19 1999-10-18 Systems for oral delivery

Publications (1)

Publication Number Publication Date
AU1071200A true AU1071200A (en) 2000-05-08

Family

ID=22302607

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10712/00A Abandoned AU1071200A (en) 1998-10-19 1999-10-18 Systems for oral delivery

Country Status (2)

Country Link
AU (1) AU1071200A (en)
WO (1) WO2000022909A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
JP4592041B2 (en) * 2000-11-24 2010-12-01 株式会社Nrlファーマ New food production methods and applications that improve quality of life
JP3973561B2 (en) * 2001-04-25 2007-09-12 田辺製薬株式会社 Potassium channel opener
EP1390383B1 (en) * 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Antisense permeation enhancers
WO2003057245A1 (en) * 2001-12-28 2003-07-17 Nrl Pharma, Inc. Compositions for improving lipid metabolism
EP2543385A1 (en) 2002-01-21 2013-01-09 NRL Pharma, Inc. Novel analgesics
US6852759B2 (en) * 2002-03-28 2005-02-08 Council Of Scientific And Industrial Research Process for the synthesis of trans-alkenoic acids, use thereof
ES2302945T3 (en) 2002-06-19 2008-08-01 Actogenix N.V. METHODS AND MEANS TO PROMOTE INTESTINAL ABSORPTION.
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
GB0308734D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
KR20120107142A (en) * 2004-01-23 2012-09-28 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Facially amphiphilic polyaryl and polyarylalkynyl polymers and olygomers and uses thereof
NZ551196A (en) * 2004-05-14 2010-08-27 Emisphere Tech Inc Compounds and compositions for delivering active agents
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP2119450B1 (en) 2005-11-29 2013-02-13 Actogenix N.V. Induction of mucosal tolerance to pancreatic islet beta-cell autoantigens
MX2008012678A (en) 2006-04-07 2008-12-17 Merrion Res Iii Ltd Solid oral dosage form containing an enhancer.
ES2492468T3 (en) 2007-01-25 2014-09-09 Actogenix N.V. Treatment of immune disease by administration through the antigen mucosa using genetically modified Lactobacillus
MX340993B (en) 2007-02-08 2016-08-02 Emisphere Tech Inc * Phenylalkylcarboxylic acid delivery agents.
US8466199B2 (en) * 2007-03-21 2013-06-18 Emisphere Technologies, Inc. Allyloxy and alkyloxy benzoic acid delivery agents
CA2723541A1 (en) 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
CA2819234A1 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
WO2012164083A1 (en) 2011-06-01 2012-12-06 Actogenix N.V. Polycistronic expression system for bacteria
CA2850187C (en) 2011-09-29 2021-12-07 Plx Pharma Inc. Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
HUE045701T2 (en) 2013-03-13 2020-01-28 Forma Therapeutics Inc 2-Hydroxy-1- {4 - [(4-phenylphenyl) carbonyl] piperazin-1-yl} ethan-1-one derivatives and related compounds as fatty acid synthase (FASN) inhibitors for the treatment of cancer
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
WO2017122180A1 (en) 2016-01-14 2017-07-20 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
US10858663B2 (en) 2016-09-02 2020-12-08 Intrexon Actobiotics N.V. Genetically modified bacteria stably expressing IL-10 and insulin
WO2018051223A1 (en) 2016-09-13 2018-03-22 Intrexon Actobiotics N.V. Mucoadhesive microorganism
JP2020502218A (en) 2016-12-21 2020-01-23 メレオ バイオファーマ 3 リミテッド Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
TWI767148B (en) 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
EP4034144A1 (en) 2019-09-27 2022-08-03 Intrexon Actobiotics NV d/b/a Precigen Actobio Treatment of celiac disease
CA3172595A1 (en) 2020-03-26 2021-09-30 Ronald Zimmerman Pharmaceutical carriers capable of ph dependent reconstitution and methods for making and using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
US4503030A (en) * 1983-06-06 1985-03-05 Alza Corporation Device for delivering drug to certain pH environments
AU608756B2 (en) * 1986-03-21 1991-04-18 Eurasiam Laboratories, Inc. Compositions for the oral administration of biologically active materials
IT1200217B (en) * 1986-09-30 1989-01-05 Valducci Roberto MEMBRANE FOR PHARMACEUTICAL AND INDUSTRIAL USE
CA1323833C (en) * 1987-04-28 1993-11-02 Yatindra M. Joshi Pharmaceutical compositions in the form of beadlets and method

Also Published As

Publication number Publication date
WO2000022909A3 (en) 2000-11-23
WO2000022909A2 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
AU1071200A (en) Systems for oral delivery
AU3385199A (en) Stent delivery system
AU1397300A (en) Oral transmucosal delivery
HUP0300246A3 (en) Delivery system
AU3268499A (en) Reversible-action endoprosthesis delivery device
AU3342599A (en) Delivery catheter
AU6956398A (en) Implant delivery system
AU1338000A (en) Rechargeable dispensing system
AU1225000A (en) Combined pharmaceutical estrogen-androgen-progestin
AU3430099A (en) Teleconferencing system
AU4549699A (en) Centerfill delivery system for nutraceuticals
EP1115377A4 (en) Semi-moist oral delivery system
AU6275399A (en) Perilaryngeal oral airway
AUPP789898A0 (en) Conveying
AU4282899A (en) Location system
AU1827799A (en) Oral delivery formulation
AU8374498A (en) Combination counter-ejector shingle-output delivery system
AU3884900A (en) Wafer delivery system
AU1409100A (en) Drugs
AU6308699A (en) Cell-cap connection system
AU2367900A (en) Chewable drug delivery system
AU5401796A (en) Solid delivery form for oral use
AU2302299A (en) Conveying system
AU5093199A (en) Transdermal delivery system
AU1875800A (en) Delivery systems for acidic actives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 14, NO 30, PAGE(S) 5476-5479 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 10712/00

MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase